Loading
A phase 2/3 trial of PM8002, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by BioNTech SE, now recruiting.
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer is a phase 2/3 interventional study registered as NCT06712316 by BioNTech SE, with 1580 participants planned, started 2025-01-07 and due to reach its primary completion in 2029-01. Interventions recorded: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/